JavaScript seems to be disabled in your browser. For the best experience on our site, be sure to turn on Javascript in your browser.

Home
Search results for: 'alzheimer'

Search results for: 'alzheimer'

A1124 Amyloid Beta-Peptide (1-40) (human)
1 Citation

Summary: residues 1-40 of human amyloid-beta

insoluble in EtOH; ≥23.8 mg/mL
A1038 Amyloid β-Peptide (10-20) (human)

Summary: Initiates neurodegeneration in Alzheimer disease

insoluble in EtOH; ≥144.7 mg/mL
A8465 LY2886721
1 Citation

Target: BACE

Summary: BACE inhibitor

insoluble in H2O; insoluble in EtOH; ≥19.52 mg/mL
A8515 Rivastigmine Tartrate

Summary: AChR inhibitor

≥20.02 mg/mL
A1039 Amyloid Beta-peptide (25-35) (human)
1 Citation

Summary: Functional domain of Aβ

insoluble in EtOH; insoluble in H2O; ≥106 mg/mL
BA8516 CAD031

Summary: CAD031 is a derivative of the Alzheimer's disease (AD)-targeting agent J147 with neuroprotective and memory-enhancing properties.
B1572 Latrepirdine

Target: Voltage-gated Calcium Channels (CaV)|NMDA receptor|adrenergic receptor|Histamine receptors|GluR|5-HT receptor|dopamine receptors|AMPA receptor

Summary: Brain cell death inhibitor

insoluble in H2O; ≥19.62 mg/mL
C8646 β-Amyloid (1-16)

Summary: β-Amyloid (1-16) is a metal-binding peptide fragment derived from β-amyloid, associated with Alzheimer's disease pathology.

Soluble in DMSO
BA8426 OAB-14

Summary: OAB-14, a Bexarotene derivative, ameliorates Alzheimer's disease-associated pathology and cognitive deficits by increasing beta-amyloid clearance in APP/PS1 mice.
BA8408 Azeliragon

Summary: Azeliragon (TTP488) is a bioavailable late-stage glycosylation end product receptor inhibitor that mitigates the progression of mild Alzheimer's disease (AD).